Efficacy and Safety of PegIntron [peginterferon alfa 2b] Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

Trial Profile

Efficacy and Safety of PegIntron [peginterferon alfa 2b] Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 27 Jan 2012 Planned end date (Jun 2008) added as reported by ClinicalTrials.gov.
    • 27 Jan 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 21 Aug 2008 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top